Carly Anderson, Cardiovascular Roundtable
An article published in Circulation this week about the safety of ICDs in athletes raises a number of questions about the effects these devices can have on various patient populations.
For the registry-based study, researchers analyzed 372 athletes with ICDs who were between the ages of 10 and 60. Participants played either organized or high-risk sports, the most common being running, basketball, soccer, and skiing. Patients were followed for a median of 31 months, and electrophysiologists examined ICD shock and clinical outcomes data every 6 months.
Play ball? Only 10% of athletes with ICDs received shocks while playing sports
The federal Department of Justice (DOJ) recently announced a novel approach to accelerate its ongoing investigation of implanted cardioverter defibrillator (ICD) procedures performed outside of CMS’s National Coverage Decision (NCD).
DOJ seeks to accelerate ICD implant investigation
Nicole MacMillan, Cardiovascular Roundtable
The introduction of novel oral anticoagulants to reduce the risk of stroke and systemic embolism in atrial fibrillation (AF) patients was hotly anticipated when the first of three new drugs hit the market in October 2010, and continues to be a frequent topic of discussion in industry journals and newsletters. While the Roundtable has covered the introduction of these new drugs in the past, we wanted to provide a more comprehensive overview of the current state of affairs, as well as what these new drugs could mean for those treating AF.
The three novel oral anticoagulants, dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto, Bayer/ Johnson & Johnson) and apixaban (Eliquis, Pfizer/ Bristol-Myers Squibb), have been expected to revolutionize stroke prevention in AF patients, offering physicians the chance to take AF patients off warfarin.
What’s going on with novel oral anticoagulants for AF?